The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis

Ebina, Kosuke; Hashimoto, Jun; Kashii, Masafumi; Hirao, Makoto; Kaneshiro, Shoichi; Noguchi, Takaaki; Tsukamoto, Yasunori; Yoshikawa, Hideki

doi:https://doi.org/10.1007/s00774-015-0731-x

The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis

Ebina, Kosuke; Hashimoto, Jun; Kashii, Masafumi et al.

Journal of Bone and Mineral Metabolism, 2017, 35(1), 91-98

Number of Access:1,032（2025-09-03 11:38 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/93257

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available	Description	information
JBoneMinerMetab_35_1_91	pdf	None	676 KB	75	2023.12.07

Item Information

Output File Export EndNote Basic Export Mendeley

Title	The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis
Creator	NRID 1000070612076 1000070612076 researchmap permalink k-ebina k-ebina Scopus Author ID 8415453300 8415453300 ORCID 0000-0002-2426-1024 0000-0002-2426-1024 CreatorName Ebina, Kosuke
	NRID 1000040237938 1000040237938 CreatorName Hashimoto, Jun
	NRID 1000000576910 1000000576910 CreatorName Kashii, Masafumi
	NRID 1000010527708 1000010527708 CreatorName Hirao, Makoto
	CreatorName Kaneshiro, Shoichi
	NRID 1000050812294 1000050812294 researchmap permalink takaakinoguchi takaakinoguchi ORCID 0000-0001-9938-6780 0000-0001-9938-6780 CreatorName Noguchi, Takaaki
	CreatorName Tsukamoto, Yasunori
	NRID 1000060191558 1000060191558 CreatorName Yoshikawa, Hideki
Subject	Daily teriparatide
	Denosumab
	Oral bisphosphonates
	Primary osteoporosis
Description	This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s00774-015-0731-x
Description	Ebina K., Hashimoto J., Kashii M., et al. The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis. Journal of Bone and Mineral Metabolism 35, 91 (2017); https://doi.org/10.1007/s00774-015-0731-x.
Abstract	The aim of this 12-month, observational study was to compare the effects of switching daily teriparatide (TPTD) to oral bisphosphonates (BP) therapy or denosumab (DMAb) therapy in patients with primary osteoporosis. Patients [n = 78; 71 postmenopausal women and seven men; mean age 76.3 (64–94) years; mean duration of prior daily TPTD therapy 20.1 (6–24) months] were allocated to either the (1) “switch-to-BP” group [n = 36; weekly alendronate 35 mg (n = 19), weekly risedronate 17.5 mg (n = 12), monthly minodronate 50 mg (n = 5)]; or (2) “switch-to-DMAb” group (n = 42; 60 mg sc every 6 months) based on each physicians’ decision. Changes in bone mineral density (BMD) and serum bone turnover markers were monitored every 6 months. No significant difference was observed in baseline clinical characteristics between the groups. After 12 months, the increase in BMD was significantly greater in the switch-to-DMAb group compared to the switch-to-BP group: lumbar spine (6.2 vs. 2.6 %; P < 0.01), total hip (4.2 vs. 1.1 %; P < 0.05), and femoral neck (3.5 vs. 1.4 %; P < 0.05). In addition, the patients in the switch-to-DMAb group showed a significant decrease compared to those in the switch-to-BP group in TRACP-5b (−55.8 vs. −32.8 %; P < 0.01) and ucOC (−85.5 vs. −65.0 %; P < 0.001), while no significant difference was observed in PINP (−67.5 vs. −62.1 %). Switching daily TPTD to DMAb significantly increased BMD and decreased bone resorption marker compared to switching to oral BP at 12 months, and thus may provide an effective sequential treatment option after daily TPTD treatment.
Publisher	Springer Nature
Source Title	Journal of Bone and Mineral Metabolism
Volume (Issue)	35(1)
Page	91-98
Date of Issued	2017-01-01
Language	English
Handle URL	https://hdl.handle.net/11094/93257
PISSN	09148779
eISSN	14355604
Relation.isVersionOf	DOI (Publisher Version) https://doi.org/10.1007/s00774-015-0731-x
Access Rights	open access
oaire:version	Accepted Manuscript
Category	学術雑誌論文 Journal Article

Resource Type	journal article
Local Type	Journal Article
DCMI Type	Text
DCTERMS.bibliographicCitation	Journal of Bone and Mineral Metabolism. 2017, 35(1), p. 91-98
DC.title	The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis
DC.creator	Ebina, Kosuke
	Hashimoto, Jun
	Kashii, Masafumi
	Hirao, Makoto
	Kaneshiro, Shoichi
	Noguchi, Takaaki
	Tsukamoto, Yasunori
	Yoshikawa, Hideki
DC.publisher	Springer Nature
DC.language' scheme='DCTERMS.RFC1766	English
DC.type' scheme='DCTERMS.DCMIType	Text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2017-01-01
DC.identifier	https://doi.org/10.1007/s00774-015-0731-x
DC.subject	Daily teriparatide
	Denosumab
	Oral bisphosphonates
	Primary osteoporosis
DC.description	This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s00774-015-0731-x
DC.description	Ebina K., Hashimoto J., Kashii M., et al. The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis. Journal of Bone and Mineral Metabolism 35, 91 (2017); https://doi.org/10.1007/s00774-015-0731-x.
DCTERMS.abstract	The aim of this 12-month, observational study was to compare the effects of switching daily teriparatide (TPTD) to oral bisphosphonates (BP) therapy or denosumab (DMAb) therapy in patients with primary osteoporosis. Patients [n = 78; 71 postmenopausal women and seven men; mean age 76.3 (64–94) years; mean duration of prior daily TPTD therapy 20.1 (6–24) months] were allocated to either the (1) “switch-to-BP” group [n = 36; weekly alendronate 35 mg (n = 19), weekly risedronate 17.5 mg (n = 12), monthly minodronate 50 mg (n = 5)]; or (2) “switch-to-DMAb” group (n = 42; 60 mg sc every 6 months) based on each physicians’ decision. Changes in bone mineral density (BMD) and serum bone turnover markers were monitored every 6 months. No significant difference was observed in baseline clinical characteristics between the groups. After 12 months, the increase in BMD was significantly greater in the switch-to-DMAb group compared to the switch-to-BP group: lumbar spine (6.2 vs. 2.6 %; P < 0.01), total hip (4.2 vs. 1.1 %; P < 0.05), and femoral neck (3.5 vs. 1.4 %; P < 0.05). In addition, the patients in the switch-to-DMAb group showed a significant decrease compared to those in the switch-to-BP group in TRACP-5b (−55.8 vs. −32.8 %; P < 0.01) and ucOC (−85.5 vs. −65.0 %; P < 0.001), while no significant difference was observed in PINP (−67.5 vs. −62.1 %). Switching daily TPTD to DMAb significantly increased BMD and decreased bone resorption marker compared to switching to oral BP at 12 months, and thus may provide an effective sequential treatment option after daily TPTD treatment.
DC.format	93257
citation_title	The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis
citation_author	Ebina, Kosuke
	Hashimoto, Jun
	Kashii, Masafumi
	Hirao, Makoto
	Kaneshiro, Shoichi
	Noguchi, Takaaki
	Tsukamoto, Yasunori
	Yoshikawa, Hideki
citation_publisher	Springer Nature
citation_language	English
citation_date	2017-01-01
citation_journal_title	Journal of Bone and Mineral Metabolism
citation_volume	35
citation_issue	1
citation_firstpage	91
citation_lastpage	98
citation_doi	https://doi.org/10.1007/s00774-015-0731-x
citation_public_url	https://hdl.handle.net/11094/93257

The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis

Link to primary information

Item Information

Show details